Trillium Asset Management LLC Takes $2.76 Million Position in TransMedics Group, Inc. $TMDX

Trillium Asset Management LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,577 shares of the company’s stock, valued at approximately $2,762,000. Trillium Asset Management LLC owned about 0.12% of TransMedics Group at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMDX. D.A. Davidson & CO. grew its position in TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after purchasing an additional 83 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. HighPoint Advisor Group LLC boosted its stake in shares of TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares during the period. Crossmark Global Holdings Inc. grew its holdings in shares of TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its position in TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX opened at $94.77 on Friday. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock’s 50 day moving average is $77.49 and its two-hundred day moving average is $95.32. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The firm has a market capitalization of $3.28 billion, a PE ratio of 24.36 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same period last year, the company posted $0.92 earnings per share. The business’s quarterly revenue was up 20.7% on a year-over-year basis. Research analysts anticipate that TransMedics Group, Inc. will post 1.47 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on TMDX. Zacks Research downgraded TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. UBS Group dropped their target price on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of “Hold” and a consensus price target of $124.18.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.